Telix to Buy Isotope Maker ITM in Deal Worth Up to $2.35 Billion

Australia's Telix Pharmaceuticals Ltd. agreed to acquire ITM Isotope Technologies Munich SE in a deal worth as much as $2.35 billion, securing a major supplier of radioactive materials used in cancer treatments and adding a late-stage drug candidate.

Telix will pay $1.65 billion upfront on a ...